Bone Metastases
- PMID: 38753755
- DOI: 10.1097/PPO.0000000000000717
Bone Metastases
Abstract
Bone metastases occur frequently in common malignancies such as breast and prostate cancer. They are responsible for considerable morbidity and skeletal-related events. Fortunately, there are now several systemic, focal, and targeted therapies that can improve quality and length of life, including radionuclide therapies. It is therefore important that bone metastases can be detected as early as possible and that treatment can be accurately and sensitively monitored. Several bone-specific and tumor-specific single-photon emission computed tomography and positron emission tomography molecular imaging agents are available, for detection and monitoring response to systemic therapeutics, as well as theranostic agents to confirm target expression and predict response to radionuclide therapies.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest and Sources of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.Lancet Oncol. 2022 Dec;23(12):1499-1507. doi: 10.1016/S1470-2045(22)00642-8. Epub 2022 Nov 4. Lancet Oncol. 2022. PMID: 36343655 Clinical Trial.
-
Prostate cancer: role of SPECT and PET in imaging bone metastases.Semin Nucl Med. 2009 Nov;39(6):396-407. doi: 10.1053/j.semnuclmed.2009.05.003. Semin Nucl Med. 2009. PMID: 19801219 Review.
-
Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer.PET Clin. 2018 Jul;13(3):383-393. doi: 10.1016/j.cpet.2018.02.002. PET Clin. 2018. PMID: 30100077 Review.
-
Bone metastases radiopharmaceuticals: an overview.Curr Radiopharm. 2013 Mar;6(1):41-7. doi: 10.2174/1874471011306010007. Curr Radiopharm. 2013. PMID: 23470032 Review.
Cited by
-
Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments.Int J Mol Sci. 2024 Jul 26;25(15):8163. doi: 10.3390/ijms25158163. Int J Mol Sci. 2024. PMID: 39125732 Free PMC article. Review.
References
-
- D'Oronzo S, Coleman R, Brown J, et al. Metastatic bone disease: pathogenesis and therapeutic option: up-date on bone metastasis management. J Bone Oncol. 2018;15:004–004.
-
- Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008;16:879–889.
-
- Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011;9:76–78.
-
- Mohan R, Kneebone A, Eade T, et al. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer. Radiat Oncol. 2023;18:127.
-
- Arvola S, Seppänen M, Timonen KL, et al. Detection of prostate cancer bone metastases with fast whole-body 99mTc-HMDP SPECT/CT using a general-purpose CZT system. EJNMMI Phys. 2022;9:85.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical